# Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer

> **NCT00548418** · PHASE2 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 27 (actual)

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** Topotecan
- **DRUG:** Cisplatin
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT00548418
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2014-08-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00548418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00548418, "Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00548418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*